The combination of PGM5‐AS1 and oxaliplatin delivered through exosomes effectively restored sensitivity to oxaliplatin in vitro and in vivo by promoting apoptosis and downregulating progestagen associated endometrial protein (PAEP), while upregulating NME1, both of which were identified as key modulators of the malignant phenotype in CRC.[103]. The gene discussed is PGM5; the disease is colorectal carcinoma.